Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

Aurélien Justet, Dymph Klay, Raphaël Porcher, Vincent Cottin, Kais Ahmad, Maria Molina Molina, Hilario Nunes, Martine Reynaud-Gaubert, Jean Marc Naccache, Effrosyni Manali, Antoine Froidure, Stéphane Jouneau, Lidwine Wemeau, Claire Andrejak, Anne Gondouin, Sandrine Hirschi, Elodie Blanchard, Benjamin Bondue, Philippe Bonniaud, Cécile Tromeur, Grégoire Prévot, Sylvain Marchand-Adam, Manuela Funke-Chambour, Anne Sophie Gamez, Ibrahima Ba, Spyridon Papiris, Jan Grutters, Bruno Crestani, Coline van Moorsel, Caroline Kannengiesser, Raphaël Borie on behalf of the OrphaLung Network
European Respiratory Journal 2021 57: 2003198; DOI: 10.1183/13993003.03198-2020
Aurélien Justet
1Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France
2OrphaLung Network, Paris, France
3Center for rare pulmonary disease, Service de Pneumologie, CHU de Caen - ISTCT, UMR6030-CNRS-CEA-Université de Caen, Caen, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dymph Klay
4Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphaël Porcher
5Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité -CRESS-UMR1153, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raphaël Porcher
Vincent Cottin
2OrphaLung Network, Paris, France
6National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent Cottin
Kais Ahmad
2OrphaLung Network, Paris, France
6National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Molina Molina
7Unit of Interstitial Lung Diseases, Dept of Pneumology, University Hospital of Bellvitge, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilario Nunes
2OrphaLung Network, Paris, France
8Reference center for rare pulmonary diseases APHP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Reynaud-Gaubert
2OrphaLung Network, Paris, France
9Center for rare pulmonary disease, Service de Pneumologie, Hôpital Nord, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Marc Naccache
2OrphaLung Network, Paris, France
10Reference center for rare pulmonary diseases, APHP, Service de Pneumologie, Hôpital Tenon, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Effrosyni Manali
11Respiratory Medicine Dept, ‘Attikon’ University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Froidure
12Cliniques Universitaires Saint-Luc, Service de Pneumologie, Bruxelles, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antoine Froidure
Stéphane Jouneau
2OrphaLung Network, Paris, France
13Center for rare pulmonary disease, Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, - IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Université de Rennes 1, Rennes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stéphane Jouneau
Lidwine Wemeau
2OrphaLung Network, Paris, France
14Reference center for rare pulmonary diseases, Service de Pneumologie, CHRU de Lille, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Andrejak
2OrphaLung Network, Paris, France
15Center for rare pulmonary disease, Service de Pneumologie, Hôpital d'Amiens, Université de Picardie Jules Verne, Amiens, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Gondouin
2OrphaLung Network, Paris, France
16Center for rare pulmonary disease CHU de Besançon, Service de Pneumologie, Besançon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandrine Hirschi
2OrphaLung Network, Paris, France
17Center for rare pulmonary disease, Service de Pneumologie, Groupe de Transplantation Pulmonaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elodie Blanchard
2OrphaLung Network, Paris, France
18Center for rare pulmonary disease, CHU de Bordeaux, Service de Pneumologie, Pessac, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Bondue
19Hôpital Erasme – ULB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Bonniaud
2OrphaLung Network, Paris, France
20Reference center for rare pulmonary diseases, Service de Pneumologie, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cécile Tromeur
2OrphaLung Network, Paris, France
21CHU de la Cavale Blanche, Département de médecine interne et de pneumologie, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grégoire Prévot
2OrphaLung Network, Paris, France
22Center for rare pulmonary diseases, Service de Pneumologie, Hôpital Larrey, Toulouse, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvain Marchand-Adam
2OrphaLung Network, Paris, France
23Center for rare pulmonary diseases, CHU de Tours, Service de Pneumologie et Explorations Fonctionnelles Respiratoires, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Funke-Chambour
24Service universitaire de pneumologie, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Sophie Gamez
2OrphaLung Network, Paris, France
25Center for rare pulmonary diseases, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHU Montpellier, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ibrahima Ba
2OrphaLung Network, Paris, France
26Dept of Genetics, APHP, Hôpital Bichat, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spyridon Papiris
11Respiratory Medicine Dept, ‘Attikon’ University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Grutters
4Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Crestani
1Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France
2OrphaLung Network, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Coline van Moorsel
4Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Kannengiesser
2OrphaLung Network, Paris, France
26Dept of Genetics, APHP, Hôpital Bichat, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Caroline Kannengiesser
Raphaël Borie
1Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France
2OrphaLung Network, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raphaël Borie
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and deadly interstitial lung disease (ILD). Over the past decade, familial occurrence of IPF led to the identification of genetic susceptibility traits [1]. Germline pathogenic variations in telomere-related genes (TRG) such as TERT, TERC TINF2, DKC1, RTEL1, PARN, NAF1, ZCCHC8, NHP2 and NOP10 have been detected in 20–30% of patients with familial pulmonary fibrosis (FPF) and in 1–5% of sporadic IPF [2–4]. In comparison with IPF patients, carriers of a TRG mutation are significantly younger and show an accelerated decline of forced vital capacity (FVC) [5–7]. Two drugs, pirfenidone and nintedanib, have been shown to reduce the decline of FVC in IPF patients [8, 9]. So far, two studies have reported on the safety and effectiveness of pirfenidone in patients with a TRG mutation [6, 7] whereas no study has investigated nintedanib in this specific population. Thus, the aim of this retrospective study was to assess safety and efficacy of nintedanib and pirfenidone in IPF patients with a TRG mutation.

Abstract

This study suggests that pirfenidone and nintedanib can be used safely in IPF patients with a telomerase related gene mutation and that both drugs reduce FVC decline. These results should be confirmed in a larger prospective study. https://bit.ly/3k7b4Zx

Acknowledgement

We thank Camille Taille, Clairelyne Dupin (Bichat Hospital, Paris) and Julie Traclet (Louis Pradel Hospital, Lyon) for their efficient collaboration and for their help in collecting the data. V. Cottin is a member of ERN-LUNG.

Footnotes

  • In an exception to usual ERJ policy, a supplementary file containing a tabulated summary of the pathogenic telomerase-related gene mutations reported in this research letter is available from erj.ersjournals.com

  • Conflict of interest: A. Justet reports grants from Roche, personal fees from Boeringher Ingelheim, outside the submitted work.

  • Conflict of interest: D. Klay has nothing to disclose.

  • Conflict of interest: R. Porcher has nothing to disclose.

  • Conflict of interest: V. Cottin reports personal fees for advisory board work and lectures, and non-financial support for meeting attendance from Actelion, grants, personal fees for consultancy and lectures, and non-financial support for meeting attendance from Boehringer Ingelheim, personal fees for advisory board and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for advisory board work and lectures from Novartis, personal fees for consultancy, lectures, steering committee and data monitoring committee work, and non-financial support for meeting attendance from Roche/Promedior, personal fees for lectures from Sanofi and AstraZeneca, personal fees for data monitoring committee work from Celgene and Galecto, personal fees for advisory board work from Shionogi, outside the submitted work.

  • Conflict of interest: K. Ahmad reports personal fees from Roche and Boeringher Ingelheim, outside the submitted work.

  • Conflict of interest: M. Molina-Molina reports grants and personal fees from Roche, Boehringer Ingelheim and Esteve-Teijin, personal fees from Chiesi, Pfizer and Galapagos, outside the submitted work.

  • Conflict of interest: H. Nunes reports personal fees from Intermune, Roche, Boehringer Ingelheim and Sanofi, outside the submitted work.

  • Conflict of interest: M. Reynaud-Gaubert has nothing to disclose.

  • Conflict of interest: J.M. Naccache has nothing to disclose.

  • Conflict of interest: E. Manali reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study.

  • Conflict of interest: A. Froidure reports grants, personal fees and non-financial support from Roche and Boehringer Ingelheim, personal fees and non-financial support from AstraZeneca, personal fees from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: S. Jouneau reports fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups, research projects over the past 3 years from AIRB, Bellorophon Therapeutics, Biogen, Boehringer, Chiesi, Fibrogen, Galecto Biotech, Genzyme, Gilead, LVL, Novartis, Olam Pharm, Pfizer, Pliant Therapeutics, Roche, Sanofi and Savara-Serendex.

  • Conflict of interest: L. Wemeau has nothing to disclose.

  • Conflict of interest: C. Andrejak has nothing to disclose.

  • Conflict of interest: A. Gondouin has nothing to disclose.

  • Conflict of interest: S. Hirschi has nothing to disclose.

  • Conflict of interest: E. Blanchard has nothing to disclose.

  • Conflict of interest: B. Bondue reports grants and personal fees from Boeringher Ingleheim and Hoffman La Roche, outside the submitted work.

  • Conflict of interest: P. Bonniaud reports personal fees from Roche, Novartis, Boeringher, TEVA and AstraZeneca, outside the submitted work.

  • Conflict of interest: C. Tromeur has nothing to disclose.

  • Conflict of interest: G. Prevot reports personal fees from Actelion, Bayer, Boehringer Ingelheim and Roche, outside the submitted work.

  • Conflict of interest: S. Marchand-Adam has nothing to disclose.

  • Conflict of interest: M. Funke-Chambour reports grants from Roche and Boehringer Ingelheim, during the conduct of the study.

  • Conflict of interest: A.S. Gamez has nothing to disclose.

  • Conflict of interest: I. Ba has nothing to disclose.

  • Conflict of interest: S. Papiris reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study.

  • Conflict of interest: J. Grutters has nothing to disclose.

  • Conflict of interest: B. Crestani reports personal fees from AstraZeneca and Sanofi, grants and personal fees from Boeringher Ingelheim and Roche, personal fees and non-financial support from BMS, outside the submitted work.

  • Conflict of interest: C. van Moorsel has nothing to disclose.

  • Conflict of interest: C. Kannengiesser has nothing to disclose.

  • Conflict of interest: R. Borie reports grants and personal fees from Boeringher Ingelheim and Roche, personal fees from Savapharma, outside the submitted work.

  • Received July 4, 2020.
  • Accepted September 9, 2020.
  • Copyright ©ERS 2021
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 2 Table of Contents
European Respiratory Journal: 57 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation
Aurélien Justet, Dymph Klay, Raphaël Porcher, Vincent Cottin, Kais Ahmad, Maria Molina Molina, Hilario Nunes, Martine Reynaud-Gaubert, Jean Marc Naccache, Effrosyni Manali, Antoine Froidure, Stéphane Jouneau, Lidwine Wemeau, Claire Andrejak, Anne Gondouin, Sandrine Hirschi, Elodie Blanchard, Benjamin Bondue, Philippe Bonniaud, Cécile Tromeur, Grégoire Prévot, Sylvain Marchand-Adam, Manuela Funke-Chambour, Anne Sophie Gamez, Ibrahima Ba, Spyridon Papiris, Jan Grutters, Bruno Crestani, Coline van Moorsel, Caroline Kannengiesser, Raphaël Borie
European Respiratory Journal Feb 2021, 57 (2) 2003198; DOI: 10.1183/13993003.03198-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation
Aurélien Justet, Dymph Klay, Raphaël Porcher, Vincent Cottin, Kais Ahmad, Maria Molina Molina, Hilario Nunes, Martine Reynaud-Gaubert, Jean Marc Naccache, Effrosyni Manali, Antoine Froidure, Stéphane Jouneau, Lidwine Wemeau, Claire Andrejak, Anne Gondouin, Sandrine Hirschi, Elodie Blanchard, Benjamin Bondue, Philippe Bonniaud, Cécile Tromeur, Grégoire Prévot, Sylvain Marchand-Adam, Manuela Funke-Chambour, Anne Sophie Gamez, Ibrahima Ba, Spyridon Papiris, Jan Grutters, Bruno Crestani, Coline van Moorsel, Caroline Kannengiesser, Raphaël Borie
European Respiratory Journal Feb 2021, 57 (2) 2003198; DOI: 10.1183/13993003.03198-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Supplementary material
    • Shareable PDF
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Clump material within drainage chest tubes contains diagnostic information
  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
Show more Agora

Research letters

  • Clump material within drainage chest tubes contains diagnostic information
  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society